Management of Breast Cancer Patients with Chemotherapy-Induced Neutropenia or Febrile Neutropenia

• Published in: Breast care (Basel, Switzerland) Vol. 9; no. 4; pp. 239 - 245
• Main Authors: Fontanella, Caterina, Bolzonello, Silvia, Lederer, Bianca, Aprile, Giuseppe
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland S. Karger GmbH 01.04.2014
• Subjects: Review; Review Article; Inpatients; Outpatients; Prognostic score; Neutropenia; Febrile neutropenia
• ISSN: 1661-3791; 1661-3805
• DOI: 10.1159/000366466

Chemotherapy-induced neutropenia (CIN) is a common toxicity caused by the administration of anticancer drugs. This side effect is associated with life-threatening infections and may alter the chemotherapy schedule, thus impacting on early and long-term outcomes. Elderly breast cancer patients with impaired health status or advanced disease as well as patients undergoing dose-dense anthracycline/taxane- or docetaxel-based regimens have the highest risk of CIN. A careful assessment of the baseline risk for CIN allows the selection of patients who need primary prophylaxis with granulocyte colony-stimulating factor (G-CSF) and/or antimicrobial agents. Neutropenic cancer patients may develop febrile neutropenia and CIN-related severe medical complications. Specific risk assessment scores, along with comprehensive clinical evaluation, are able to define a group of febrile patients with low risk for complications who can be safely treated as outpatients. Conversely, patients with higher risk of severe complications should be hospitalized and should receive intravenous antibiotic therapy with or without G-CSF.